Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients With TP53-Mutated, HER2 Negative Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

NCT05622058 is registered in ClinicalTrials.gov with Aileron Therapeutics, Inc. as lead sponsor.

NCT NCT05622058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05622058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients With TP53-Mutated, HER2 Negative Breast Cancer Receiving Neoadjuvant or Adjuvant Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Lead sponsor
Aileron Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 9, 2023
Completion date
February 22, 2023
Enrollment
6 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of chemotherapy-induced myelosuppression